{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}],"title":"recovery of absolute neutrophil count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"maximum of 20 days of treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"}]}],"title":"premature discontinuation: occurence of fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"premature discontinuation: antibiotic treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"premature discontinuation: death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}],"title":"premature discontinuation: other adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"title":"premature discontinuation: other reason"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Absolute neutrophil count (ANC) recovered to \\> 500 /µl on two consecutive days Maximum of 20 days of treatment Occurrence of fever \\>= 38°C Systemic antibiotic treatment despite patient being afebrile Death Other adverse event (AE) Other reason","groups":[{"description":"moxifloxacin 400 mg tablets once daily","id":"OG000","title":"Moxifloxacin"},{"description":"identical appearing placebo","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"intention to treat (ITT)","reportingStatus":"POSTED","timeFrame":"end of treatment (mean duration of treatment was 9.7 days; 10.2 days in moxifloxacin arm, 9.2 days in placebo arm)","title":"Reason for Discontinuation of Treatment","type":"SECONDARY","unitOfMeasure":"participants"}